Epilepsy research · 2025
Principal component analysis of antiseizure medication-induced hostility/aggression and factor analysis of levetiracetam using the food and drug administration adverse event reporting system.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hosoya Ryuichiro, Kitajima Kento, Sogawa Koushirou, Ikegami Daigo, Terajima Tomoko, Kato Hideaki, Funada Masahiko, Kagaya Hajime, Uesawa Yoshihiro
Аннотация
BACKGROUND: Epilepsy affects approximately 50 million people worldwide. Antiseizure medications (ASMs) are essential for seizure control. However, adverse psychiatric effects, particularly hostility and aggression, affect treatment adherence and the quality of life. The risk factors and mechanisms underlying these adverse effects remain unclear.
OBJECTIVE: This study aimed to classify ASM-induced hostility/aggression using the Food and Drug Administration Adverse Event Reporting System (FAERS), a global pharmacovigilance database, focusing on the risk factors and onset patterns of levetiracetam-induced hostility/aggression.
METHODS: The FAERS database (2004 Q1-2022 Q1) was analyzed to calculate the reporting odds ratios for ASM-induced hostility/aggression, which were classified using a principal component analysis. Levetiracetam-induced adverse effects and the associated independent risk factors were examined. Weibull distribution analysis was used to assess the time-to-onset patterns RESULTS: Principal component analysis identified eight ASM-induced adverse effects, including "aggression," "anger," "homicidal ideation," and "hostility." In those taking levetiracetam aged ≥ 12 years, male sex, younger age, and specific concomitant medications were independent risk factors for levetiracetam-induced adverse effects. Levetiracetam-induced adverse effects exhibited an early failure pattern, with a median onset of 4.5 days in patients aged ≥ 12 years and 1.5 days in those < 12 years.
CONCLUSION: In this study, we classified ASM-induced hostility/aggression and estimated the risk factors for levetiracetam-induced adverse effects. In particular, we identified early-onset patterns and high-risk patient profiles. These findings are consistent with clinical observations and provide insight into the mechanisms underlying these adverse effects, which will contribute to proactive risk management and personalized treatment strategies.
OBJECTIVE: This study aimed to classify ASM-induced hostility/aggression using the Food and Drug Administration Adverse Event Reporting System (FAERS), a global pharmacovigilance database, focusing on the risk factors and onset patterns of levetiracetam-induced hostility/aggression.
METHODS: The FAERS database (2004 Q1-2022 Q1) was analyzed to calculate the reporting odds ratios for ASM-induced hostility/aggression, which were classified using a principal component analysis. Levetiracetam-induced adverse effects and the associated independent risk factors were examined. Weibull distribution analysis was used to assess the time-to-onset patterns RESULTS: Principal component analysis identified eight ASM-induced adverse effects, including "aggression," "anger," "homicidal ideation," and "hostility." In those taking levetiracetam aged ≥ 12 years, male sex, younger age, and specific concomitant medications were independent risk factors for levetiracetam-induced adverse effects. Levetiracetam-induced adverse effects exhibited an early failure pattern, with a median onset of 4.5 days in patients aged ≥ 12 years and 1.5 days in those < 12 years.
CONCLUSION: In this study, we classified ASM-induced hostility/aggression and estimated the risk factors for levetiracetam-induced adverse effects. In particular, we identified early-onset patterns and high-risk patient profiles. These findings are consistent with clinical observations and provide insight into the mechanisms underlying these adverse effects, which will contribute to proactive risk management and personalized treatment strategies.
Предметные рубрики MeSH
HumansLevetiracetamAggressionMaleAnticonvulsantsFemaleHostilityAdverse Drug Reaction Reporting SystemsPrincipal Component AnalysisAdultUnited StatesMiddle AgedUnited States Food and Drug AdministrationAdolescentYoung AdultAgedChildEpilepsyFactor Analysis, StatisticalPharmacovigilanceRisk FactorsChild, Preschool